Bausch + Lomb BLCO Pharmaceuticals — Goodwill, Foreign Currency Translation, Gain (Loss)
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bausch + Lomb in its filing.
Tagged under the XBRL concept us-gaap:GoodwillForeignCurrencyTranslationGainLoss.
The official record: Bausch + Lomb’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bausch + Lomb's pharmaceuticals — goodwill, foreign currency translation, gain (loss).
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bausch + Lomb's pharmaceuticals — goodwill, foreign currency translation, gain (loss)?
- Bausch + Lomb (BLCO) reported pharmaceuticals — goodwill, foreign currency translation, gain (loss) of $13M in Q1 2026.
- How has Bausch + Lomb's pharmaceuticals — goodwill, foreign currency translation, gain (loss) changed year-over-year?
- Bausch + Lomb's pharmaceuticals — goodwill, foreign currency translation, gain (loss) increased by 139.4% year-over-year, from -$33M to $13M.
- What is the long-term trend for Bausch + Lomb's pharmaceuticals — goodwill, foreign currency translation, gain (loss)?
- Over 3 years (2021 to 2025), Bausch + Lomb's pharmaceuticals — goodwill, foreign currency translation, gain (loss) has grown at a 95.7% compound annual growth rate (CAGR), from $14M to -$105M.
- What does pharmaceuticals — goodwill, foreign currency translation, gain (loss) mean?
- Captures the impact of exchange rate fluctuations on the carrying value of goodwill denominated in foreign currencies within the pharmaceutical segment. It reflects non-operating volatility that arises when reporting international pharmaceutical assets in the company's functional reporting currency.